BR112015027561A8 - formulação de rede reticulada por nanopartícula injetável e polimérica, e uso da mesma - Google Patents

formulação de rede reticulada por nanopartícula injetável e polimérica, e uso da mesma Download PDF

Info

Publication number
BR112015027561A8
BR112015027561A8 BR112015027561A BR112015027561A BR112015027561A8 BR 112015027561 A8 BR112015027561 A8 BR 112015027561A8 BR 112015027561 A BR112015027561 A BR 112015027561A BR 112015027561 A BR112015027561 A BR 112015027561A BR 112015027561 A8 BR112015027561 A8 BR 112015027561A8
Authority
BR
Brazil
Prior art keywords
glucose
injectable
insulin
formulation
delivery
Prior art date
Application number
BR112015027561A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112015027561A2 (pt
Inventor
Arthur Aimetti Alex
G Anderson Daniel
S Langer Robert
Gu Zhen
Original Assignee
Massachusetts Inst Technology
Childrens Medical Ct Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology, Childrens Medical Ct Corp filed Critical Massachusetts Inst Technology
Publication of BR112015027561A2 publication Critical patent/BR112015027561A2/pt
Publication of BR112015027561A8 publication Critical patent/BR112015027561A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y40/00—Manufacture or treatment of nanostructures

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
BR112015027561A 2013-04-30 2014-04-29 formulação de rede reticulada por nanopartícula injetável e polimérica, e uso da mesma BR112015027561A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361817752P 2013-04-30 2013-04-30
US201361864069P 2013-08-09 2013-08-09
PCT/US2014/035927 WO2014179344A1 (en) 2013-04-30 2014-04-29 Injectable nano-network gels for diabetes treatment

Publications (2)

Publication Number Publication Date
BR112015027561A2 BR112015027561A2 (pt) 2017-07-25
BR112015027561A8 true BR112015027561A8 (pt) 2019-12-24

Family

ID=51843897

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015027561A BR112015027561A8 (pt) 2013-04-30 2014-04-29 formulação de rede reticulada por nanopartícula injetável e polimérica, e uso da mesma

Country Status (11)

Country Link
US (1) US20160067190A1 (https=)
EP (1) EP2991673A4 (https=)
JP (1) JP2016517885A (https=)
KR (1) KR20160024853A (https=)
CN (1) CN105813652A (https=)
AU (1) AU2014260024B2 (https=)
BR (1) BR112015027561A8 (https=)
HK (2) HK1221415A1 (https=)
MX (1) MX2015015079A (https=)
RU (1) RU2015151135A (https=)
WO (1) WO2014179344A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014153114A1 (en) * 2013-03-14 2014-09-25 Fred Hutchinson Cancer Research Center Compositions and methods to modify cells for therapeutic objectives
JP2017538728A (ja) * 2014-12-19 2017-12-28 ケミン、インダストリーズ、インコーポレーテッドＫｅｍｉｎ Ｉｎｄｕｓｔｒｉｅｓ， Ｉｎｃ． イオントフォレシスを用いた生物活性分子の眼内送達
CN104740641B (zh) * 2015-04-08 2019-02-01 烟台大学 一种糖敏感的缓控释微球组合物及其制备方法
RU2719584C2 (ru) * 2015-04-21 2020-04-21 Норт Каролина Стейт Юниверсити Глюкозочувствительная система доставки инсулина с использованием чувствительных к гипоксии нанокомпозитов
JP6757464B2 (ja) * 2016-07-21 2020-09-16 ボストン サイエンティフィック サイムド，インコーポレイテッドＢｏｓｔｏｎ Ｓｃｉｅｎｔｉｆｉｃ Ｓｃｉｍｅｄ，Ｉｎｃ． 注射用組成物
WO2018085809A1 (en) 2016-11-07 2018-05-11 North Carolina State University Patch loaded with dual-sensitive vesicles for enhanced glucose-responsive insulin delivery
EP3799865B1 (en) * 2016-12-05 2022-06-15 North Carolina State University Core-shell microneedle devices and uses thereof
CN106668840B (zh) * 2017-02-10 2020-02-14 南通大学 一种胰岛素控释药物及其制备方法与应用
WO2019055594A1 (en) * 2017-09-13 2019-03-21 North Carolina State University BRUSHING ADIPOSE TISSUE INDUCED LOCALLY BY MICRO-NEEDLE STAMPS FOR THE TREATMENT OF OBESITY
CN111629746B (zh) * 2017-11-21 2024-04-16 北卡罗来纳州立大学 具有超快响应的用于葡萄糖触发胰岛素递送的电荷可切换聚合物储库
EP3735262A4 (en) * 2018-01-03 2021-09-29 Penn State Research Foundation GLUCOSE OXIDASE COMPOSITIONS AS ANTICONVULSIVE FOR NEWBORN
CN111629715A (zh) 2018-01-18 2020-09-04 弗莱德哈钦森癌症研究中心 通过调节细胞活化状态改变体内免疫细胞的炎症状态
CN111195238A (zh) * 2018-10-31 2020-05-26 南方医科大学 一种用于胰岛素口服递送的聚电解质复合物
US20220204654A1 (en) * 2019-04-25 2022-06-30 Massachusetts Institute Of Technology Cyclodextrin supramolecular scaffolds and uses thereof
CN115350267B (zh) * 2022-07-19 2025-01-14 深圳大学 一种级联催化型纳米治疗剂及其制备方法和应用
CN115252537B (zh) * 2022-09-01 2026-02-06 西北大学 用于糖尿病伤口的双层微针贴片及其制备方法
CN116474162B (zh) * 2023-04-28 2024-08-16 吉林大学 一种用于糖尿病慢性创伤修复的自修复水凝胶的制备方法
US20250025411A1 (en) * 2023-07-21 2025-01-23 Massachusetts Institute Of Technology Readily soluble and thermostable glucagon formulations and delivery for mini-dosing and closed -loop prophylactic treatment of hypoglycemia

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US6497903B1 (en) * 1996-07-01 2002-12-24 Wilhelmus Everhardus Hennink Hydrolysable hydrogels for controlled release
AU2003301064A1 (en) * 2002-12-17 2004-07-14 Massachusetts Institute Of Technology Stimuli-responsive systems for controlled drug delivery
WO2006088473A2 (en) * 2004-04-23 2006-08-24 Panduranga Rao Koritala Microcapsules and nanocapsules for the transmucosal delivery of therapeutic and diagnostic agents
EP1595534A1 (en) * 2004-05-13 2005-11-16 Universiteit Utrecht Holding B.V. Gel composition comprising charged polymers
TWI394580B (zh) * 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
JP5841708B2 (ja) * 2008-07-01 2016-01-13 日東電工株式会社 表面被覆微粒子の医薬組成物

Also Published As

Publication number Publication date
RU2015151135A (ru) 2017-06-02
CN105813652A (zh) 2016-07-27
JP2016517885A (ja) 2016-06-20
MX2015015079A (es) 2016-07-05
EP2991673A1 (en) 2016-03-09
HK1222546A1 (zh) 2017-07-07
US20160067190A1 (en) 2016-03-10
EP2991673A4 (en) 2016-12-21
WO2014179344A1 (en) 2014-11-06
AU2014260024B2 (en) 2016-09-15
BR112015027561A2 (pt) 2017-07-25
KR20160024853A (ko) 2016-03-07
AU2014260024A1 (en) 2015-11-19
HK1221415A1 (zh) 2017-06-02

Similar Documents

Publication Publication Date Title
BR112015027561A8 (pt) formulação de rede reticulada por nanopartícula injetável e polimérica, e uso da mesma
Xin et al. A review on thermal properties of hydrogels for electronic devices applications
CL2017002652A1 (es) Sistema de suministro de insulina sensible a la glucosa usando nanocompuestos sensibles a la hipoxia
BR112014014832A8 (pt) formulação e método de controlar fungos
MX2014009480A (es) Metodo compartimentado de administracion de acidos nucleicos y composiciones y usos del mismo.
MX387891B (es) Preparación inyectable que comprende una composición en gel de aripiprazol y polinilpirrolidona como agente de suspensión y el uso de la misma para tratar esquizofrenia, trastorno bipolar o depresión
BR112015005878A2 (pt) nanopartículas terapêuticas compreendendo agente terapêutico e métodos de preparar e usar as mesmas
BR112014016562A2 (pt) estrutura de oligo-rna de dupla hélice, nanopartícula e método de preparação
BR112013007740A2 (pt) métodos para processamento de microesferas, microesferas processadas por tais métodos e seus usos
UA117480C2 (uk) Лікування цукрового діабету за допомогою складу інсуліну тривалої дії
NI201400122A (es) Agentes terapéuticos para administración subcutánea optimizados
UY33417A (es) Formulación que contiene acido azelaico con adición de pigmento
BR112013024863A2 (pt) formulação injetável de liberação sustentada
PL401997A1 (pl) Sposób wytwarzania nanokrystalicznego tytanu, zwłaszcza na implanty medyczne, oraz tytanowy implant medyczny
AR074406A1 (es) Celulas madre terapeuticas derivadas de monocitos humanos y un metodo para inducir celulas madre terapeuticas derivadas de monocitos humanos
BR112013027006A2 (pt) método de produzir substâncias com gás supersaturado, dispositivo de distribuição transdérmica do mesmo
AR085655A1 (es) Extracto de cinnamomum burmanii, proceso de extraccion y su uso como regulador por disminucion de la bomba de protones, inhibidor enzimatico, y mucoprotector
Liu et al. Hydrogel–Flexible Electronics Integrated Platforms for Diabetic Wound Management
ES2559654T3 (es) Procedimiento de producción continua de una dispersión acuosa de resina de poli(met)acrilato
Palanimuthu et al. Wound healing activities of eugenia jambolana lam. Bark extracts in albino rats.
BR112012031507A2 (pt) método para a liberação sustentada de um composto ativo como inseticida
WEI et al. Application of artificial intelligence in diagnosis of diabetes
HWANG et al. A case of psoriasiform Tinea corporis caused by Microsporum canis
RS20100499A2 (en) OBTAINING MICROPARTICLES OF ALGINATE HYDROGELS WITH INCORPORATED SILVER NANOPARTICLES
Equality 56 RelativeRiskCrossOver. Equivalence

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]